Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 107 entries
Sorted by: Best Match Show Resources per page
Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients.

Case reports in oncology

Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H.
PMID: 28512412
Case Rep Oncol. 2017 Apr 04;10(1):290-295. doi: 10.1159/000461576. eCollection 2017.

Vemurafenib is an inhibitor of the BRAF mutation and has been approved by the Food and Drug Administration as a treatment option for patients with unresectable melanoma without brain metastasis. In the literature, vemurafenib has been reported to be...

Cite
Imafuku K, Yoshino K, Yamaguchi K, et al. Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients. Case Rep Oncol. 2017;10(1):290-295doi: 10.1159/000461576.
Imafuku, K., Yoshino, K., Yamaguchi, K., Tsuboi, S., Ohara, K., & Hata, H. (2017). Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients. Case reports in oncology, 10(1), 290-295. https://doi.org/10.1159/000461576
Imafuku, Keisuke, et al. "Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients." Case reports in oncology vol. 10,1 (2017): 290-295. doi: https://doi.org/10.1159/000461576
Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients. Case Rep Oncol. 2017 Apr 04;10(1):290-295. doi: 10.1159/000461576. eCollection 2017. PMID: 28512412; PMCID: PMC5422723.
Copy Download .nbib Format: NLM
Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events.

Case reports in oncology

Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H.
PMID: 28512413
Case Rep Oncol. 2017 Apr 04;10(1):296-300. doi: 10.1159/000463379. eCollection 2017.

Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis. Prednisolone can effectively treat irAEs. However, it is...

Cite
Imafuku K, Yoshino K, Yamaguchi K, et al. Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case Rep Oncol. 2017;10(1):296-300doi: 10.1159/000463379.
Imafuku, K., Yoshino, K., Yamaguchi, K., Tsuboi, S., Ohara, K., & Hata, H. (2017). Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case reports in oncology, 10(1), 296-300. https://doi.org/10.1159/000463379
Imafuku, Keisuke, et al. "Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events." Case reports in oncology vol. 10,1 (2017): 296-300. doi: https://doi.org/10.1159/000463379
Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case Rep Oncol. 2017 Apr 04;10(1):296-300. doi: 10.1159/000463379. eCollection 2017. PMID: 28512413; PMCID: PMC5422733.
Copy Download .nbib Format: NLM
Heavy Element Effects in the Diagonal Born-Oppenheimer Correction within a Relativistic Spin-Free Hamiltonian.

The journal of physical chemistry. A

Imafuku Y, Abe M, Schmidt MW, Hada M.
PMID: 27003510
J Phys Chem A. 2016 Apr 07;120(13):2150-9. doi: 10.1021/acs.jpca.6b01507. Epub 2016 Mar 29.

Methodologies beyond the Born-Oppenheimer (BO) approximation are nowadays important to explain high precision spectroscopic measurements. Most previous evaluations of the BO correction are, however, focused on light-element molecules and based on a nonrelativistic Hamiltonian, so no information about the...

Cite
Imafuku Y, Abe M, Schmidt MW, et al. Heavy Element Effects in the Diagonal Born-Oppenheimer Correction within a Relativistic Spin-Free Hamiltonian. J Phys Chem A. 2016;120(13):2150-9doi: 10.1021/acs.jpca.6b01507.
Imafuku, Y., Abe, M., Schmidt, M. W., & Hada, M. (2016). Heavy Element Effects in the Diagonal Born-Oppenheimer Correction within a Relativistic Spin-Free Hamiltonian. The journal of physical chemistry. A, 120(13), 2150-9. https://doi.org/10.1021/acs.jpca.6b01507
Imafuku, Yuji, et al. "Heavy Element Effects in the Diagonal Born-Oppenheimer Correction within a Relativistic Spin-Free Hamiltonian." The journal of physical chemistry. A vol. 120,13 (2016): 2150-9. doi: https://doi.org/10.1021/acs.jpca.6b01507
Imafuku Y, Abe M, Schmidt MW, Hada M. Heavy Element Effects in the Diagonal Born-Oppenheimer Correction within a Relativistic Spin-Free Hamiltonian. J Phys Chem A. 2016 Apr 07;120(13):2150-9. doi: 10.1021/acs.jpca.6b01507. Epub 2016 Mar 29. PMID: 27003510.
Copy Download .nbib Format: NLM
Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration.

Case reports in oncology

Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H.
PMID: 28559821
Case Rep Oncol. 2017 Apr 24;10(1):368-371. doi: 10.1159/000471480. eCollection 2017.

Immune checkpoint inhibitors have drastically changed in the treatment of many kinds of malignancies, especially malignant melanoma. The focus of the recent experiments has not only been on their efficacy but also immune-related adverse events (irAEs). We report a...

Cite
Imafuku K, Yoshino K, Yamaguchi K, et al. Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration. Case Rep Oncol. 2017;10(1):368-371doi: 10.1159/000471480.
Imafuku, K., Yoshino, K., Yamaguchi, K., Tsuboi, S., Ohara, K., & Hata, H. (2017). Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration. Case reports in oncology, 10(1), 368-371. https://doi.org/10.1159/000471480
Imafuku, Keisuke, et al. "Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration." Case reports in oncology vol. 10,1 (2017): 368-371. doi: https://doi.org/10.1159/000471480
Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration. Case Rep Oncol. 2017 Apr 24;10(1):368-371. doi: 10.1159/000471480. eCollection 2017. PMID: 28559821; PMCID: PMC5436031.
Copy Download .nbib Format: NLM
Synthesis of poly(6-azulenylethynyl)benzene derivatives as a multielectron redox system with liquid crystalline behavior.

Journal of the American Chemical Society

Ito S, Inabe H, Morita N, Ohta K, Kitamura T, Imafuku K.
PMID: 12568629
J Am Chem Soc. 2003 Feb 12;125(6):1669-80. doi: 10.1021/ja0209262.

A series of poly(6-azulenylethynyl)benzenes substituted with n-hexyloxycarbonyl chains at 1,3-positions in azulene rings, i.e., hexakis-, 1,2,4,5-tetrakis-, 1,3,5-tris-, and 1,4-bis(6-azulenylethynyl)benzene derivatives 1, 2, 3, and 4b, have been prepared by a simple one-pot reaction involving repeated Pd-catalyzed alkynylation of halogenated...

Cite
Ito S, Inabe H, Morita N, et al. Synthesis of poly(6-azulenylethynyl)benzene derivatives as a multielectron redox system with liquid crystalline behavior. J Am Chem Soc. 2003;125(6):1669-80doi: 10.1021/ja0209262.
Ito, S., Inabe, H., Morita, N., Ohta, K., Kitamura, T., & Imafuku, K. (2003). Synthesis of poly(6-azulenylethynyl)benzene derivatives as a multielectron redox system with liquid crystalline behavior. Journal of the American Chemical Society, 125(6), 1669-80. https://doi.org/10.1021/ja0209262
Ito, Shunji, et al. "Synthesis of poly(6-azulenylethynyl)benzene derivatives as a multielectron redox system with liquid crystalline behavior." Journal of the American Chemical Society vol. 125,6 (2003): 1669-80. doi: https://doi.org/10.1021/ja0209262
Ito S, Inabe H, Morita N, Ohta K, Kitamura T, Imafuku K. Synthesis of poly(6-azulenylethynyl)benzene derivatives as a multielectron redox system with liquid crystalline behavior. J Am Chem Soc. 2003 Feb 12;125(6):1669-80. doi: 10.1021/ja0209262. PMID: 12568629.
Copy Download .nbib Format: NLM
Synthesis and redox behavior of azulene-substituted benzene derivatives and (eta(5)-cyclopentadienyl)[tetra- and di(6-azulenyl)cyclobutadiene]cobalt complexes.

The Journal of organic chemistry

Ito S, Inabe H, Okujima T, Morita N, Watanabe M, Harada N, Imafuku K.
PMID: 11597235
J Org Chem. 2001 Oct 19;66(21):7090-101. doi: 10.1021/jo010540u.

1,2-Di(6-azulenyl)tetraphenylbenzenes and (6-azulenyl)pentaphenylbenzenes were synthesized by Diels-Alder reactions of di(6-azulenyl)acetylenes and 6-(phenylethynyl)azulenes with tetraphenylcyclopentadienone. Cobalt-mediated cyclooligomerization of mono- and di(6-azulenyl)acetylenes afforded 1,3,5- and 1,2,4-tri(6-azulenyl)benzene derivatives together with (eta(5)-cyclopentadienyl)[tetra- and di(6-azulenyl)cyclobutadiene]cobalt complexes. The redox behavior of these novel (6-azulenyl)benzene derivatives...

Cite
Ito S, Inabe H, Okujima T, et al. Synthesis and redox behavior of azulene-substituted benzene derivatives and (eta(5)-cyclopentadienyl)[tetra- and di(6-azulenyl)cyclobutadiene]cobalt complexes. J Org Chem. 2001;66(21):7090-101doi: 10.1021/jo010540u.
Ito, S., Inabe, H., Okujima, T., Morita, N., Watanabe, M., Harada, N., & Imafuku, K. (2001). Synthesis and redox behavior of azulene-substituted benzene derivatives and (eta(5)-cyclopentadienyl)[tetra- and di(6-azulenyl)cyclobutadiene]cobalt complexes. The Journal of organic chemistry, 66(21), 7090-101. https://doi.org/10.1021/jo010540u
Ito, S, et al. "Synthesis and redox behavior of azulene-substituted benzene derivatives and (eta(5)-cyclopentadienyl)[tetra- and di(6-azulenyl)cyclobutadiene]cobalt complexes." The Journal of organic chemistry vol. 66,21 (2001): 7090-101. doi: https://doi.org/10.1021/jo010540u
Ito S, Inabe H, Okujima T, Morita N, Watanabe M, Harada N, Imafuku K. Synthesis and redox behavior of azulene-substituted benzene derivatives and (eta(5)-cyclopentadienyl)[tetra- and di(6-azulenyl)cyclobutadiene]cobalt complexes. J Org Chem. 2001 Oct 19;66(21):7090-101. doi: 10.1021/jo010540u. PMID: 11597235.
Copy Download .nbib Format: NLM
New transmission-type X-ray filters consisting of amorphous multilayer films.

Journal of synchrotron radiation

Takagi Y, Imafuku M.
PMID: 15263592
J Synchrotron Radiat. 1998 May 01;5:603-5. doi: 10.1107/S0909049598001496. Epub 1998 May 01.

New transmission-type X-ray filters have been developed. The filters consist of X-ray-amorphous metal (less than 30 A)/metalloid ( approximately 10 A) multilayer films sputter-deposited on X-ray-transparent polymer substrates. Such metal/metalloid multilayer films show only very broad diffraction peaks, since...

Cite
Takagi Y, Imafuku M. New transmission-type X-ray filters consisting of amorphous multilayer films. J Synchrotron Radiat. 1998;5:603-5doi: 10.1107/S0909049598001496.
Takagi, Y., & Imafuku, M. (1998). New transmission-type X-ray filters consisting of amorphous multilayer films. Journal of synchrotron radiation, 5603-5. https://doi.org/10.1107/S0909049598001496
Takagi, Y, and Imafuku, M. "New transmission-type X-ray filters consisting of amorphous multilayer films." Journal of synchrotron radiation vol. 5 (1998): 603-5. doi: https://doi.org/10.1107/S0909049598001496
Takagi Y, Imafuku M. New transmission-type X-ray filters consisting of amorphous multilayer films. J Synchrotron Radiat. 1998 May 01;5:603-5. doi: 10.1107/S0909049598001496. Epub 1998 May 01. PMID: 15263592.
Copy Download .nbib Format: NLM
Effect of contrast material (Levovist) infusion on peak systolic velocity in middle cerebral artery using transcranial color-coded duplex sonography.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

Hamaguchi H, Kanda F, Imafuku I, Kunimoto M, Chihara K.
PMID: 17903986
J Stroke Cerebrovasc Dis. 2004 Nov-Dec;13(6):267-70. doi: 10.1016/j.jstrokecerebrovasdis.2004.07.005.

It is of crucial importance to predict the presence of stenosis in cerebral artery before occurrence of a stroke. To determine stenosis in the middle cerebral artery (MCA), we examined the effect of contrast agent (Levovist) infusion on transcranial...

Cite
Hamaguchi H, Kanda F, Imafuku I, et al. Effect of contrast material (Levovist) infusion on peak systolic velocity in middle cerebral artery using transcranial color-coded duplex sonography. J Stroke Cerebrovasc Dis. 2004;13(6):267-70doi: 10.1016/j.jstrokecerebrovasdis.2004.07.005.
Hamaguchi, H., Kanda, F., Imafuku, I., Kunimoto, M., & Chihara, K. (2004). Effect of contrast material (Levovist) infusion on peak systolic velocity in middle cerebral artery using transcranial color-coded duplex sonography. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 13(6), 267-70. https://doi.org/10.1016/j.jstrokecerebrovasdis.2004.07.005
Hamaguchi, Hirotoshi, et al. "Effect of contrast material (Levovist) infusion on peak systolic velocity in middle cerebral artery using transcranial color-coded duplex sonography." Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association vol. 13,6 (2004): 267-70. doi: https://doi.org/10.1016/j.jstrokecerebrovasdis.2004.07.005
Hamaguchi H, Kanda F, Imafuku I, Kunimoto M, Chihara K. Effect of contrast material (Levovist) infusion on peak systolic velocity in middle cerebral artery using transcranial color-coded duplex sonography. J Stroke Cerebrovasc Dis. 2004 Nov-Dec;13(6):267-70. doi: 10.1016/j.jstrokecerebrovasdis.2004.07.005. PMID: 17903986.
Copy Download .nbib Format: NLM
Observation of a large reaction cross section in the drip-line nucleus 22C.

Physical review letters

Tanaka K, Yamaguchi T, Suzuki T, Ohtsubo T, Fukuda M, Nishimura D, Takechi M, Ogata K, Ozawa A, Izumikawa T, Aiba T, Aoi N, Baba H, Hashizume Y, Inafuku K, Iwasa N, Kobayashi K, Komuro M, Kondo Y, Kubo T, Kurokawa M, Matsuyama T, Michimasa S, Motobayashi T, Nakabayashi T, Nakajima S, Nakamura T, Sakurai H, Shinoda R, Shinohara M, Suzuki H, Takeshita E, Takeuchi S, Togano Y, Yamada K, Yasuno T, Yoshitake M.
PMID: 20366816
Phys Rev Lett. 2010 Feb 12;104(6):062701. doi: 10.1103/PhysRevLett.104.062701. Epub 2010 Feb 08.

Reaction cross sections (sigma(R)) for 19C, 20C and the drip-line nucleus 22C on a liquid hydrogen target have been measured at around 40A MeV by a transmission method. A large enhancement of sigma(R) for 22C compared to those for...

Cite
Tanaka K, Yamaguchi T, Suzuki T, et al. Observation of a large reaction cross section in the drip-line nucleus 22C. Phys Rev Lett. 2010;104(6):062701doi: 10.1103/PhysRevLett.104.062701.
Tanaka, K., Yamaguchi, T., Suzuki, T., Ohtsubo, T., Fukuda, M., Nishimura, D., Takechi, M., Ogata, K., Ozawa, A., Izumikawa, T., Aiba, T., Aoi, N., Baba, H., Hashizume, Y., Inafuku, K., Iwasa, N., Kobayashi, K., Komuro, M., Kondo, Y., Kubo, T., Kurokawa, M., Matsuyama, T., Michimasa, S., Motobayashi, T., Nakabayashi, T., Nakajima, S., Nakamura, T., Sakurai, H., Shinoda, R., Shinohara, M., Suzuki, H., Takeshita, E., Takeuchi, S., Togano, Y., Yamada, K., Yasuno, T., & Yoshitake, M. (2010). Observation of a large reaction cross section in the drip-line nucleus 22C. Physical review letters, 104(6), 062701. https://doi.org/10.1103/PhysRevLett.104.062701
Tanaka, K, et al. "Observation of a large reaction cross section in the drip-line nucleus 22C." Physical review letters vol. 104,6 (2010): 062701. doi: https://doi.org/10.1103/PhysRevLett.104.062701
Tanaka K, Yamaguchi T, Suzuki T, Ohtsubo T, Fukuda M, Nishimura D, Takechi M, Ogata K, Ozawa A, Izumikawa T, Aiba T, Aoi N, Baba H, Hashizume Y, Inafuku K, Iwasa N, Kobayashi K, Komuro M, Kondo Y, Kubo T, Kurokawa M, Matsuyama T, Michimasa S, Motobayashi T, Nakabayashi T, Nakajima S, Nakamura T, Sakurai H, Shinoda R, Shinohara M, Suzuki H, Takeshita E, Takeuchi S, Togano Y, Yamada K, Yasuno T, Yoshitake M. Observation of a large reaction cross section in the drip-line nucleus 22C. Phys Rev Lett. 2010 Feb 12;104(6):062701. doi: 10.1103/PhysRevLett.104.062701. Epub 2010 Feb 08. PMID: 20366816.
Copy Download .nbib Format: NLM
Evaluation of the local environment for nanoscale quasicrystal formation in Zr(80)Pt(20) glassy alloy using Voronoi analysis.

Journal of physics. Condensed matter : an Institute of Physics journal

Saida J, Itoh K, Sato S, Imafuku M, Sanada T, Inoue A.
PMID: 21832335
J Phys Condens Matter. 2009 Sep 16;21(37):375104. doi: 10.1088/0953-8984/21/37/375104. Epub 2009 Aug 11.

The local atomic structure of nano-quasicrystal-forming Zr(80)Pt(20) binary glassy alloy was investigated by reverse Monte Carlo modeling based on the results of x-ray diffraction. A prepeak at Q∼17 nm(-1) originating from the unique bonding between the Pt-Pt pair is...

Cite
Saida J, Itoh K, Sato S, et al. Evaluation of the local environment for nanoscale quasicrystal formation in Zr(80)Pt(20) glassy alloy using Voronoi analysis. J Phys Condens Matter. 2009;21(37):375104doi: 10.1088/0953-8984/21/37/375104.
Saida, J., Itoh, K., Sato, S., Imafuku, M., Sanada, T., & Inoue, A. (2009). Evaluation of the local environment for nanoscale quasicrystal formation in Zr(80)Pt(20) glassy alloy using Voronoi analysis. Journal of physics. Condensed matter : an Institute of Physics journal, 21(37), 375104. https://doi.org/10.1088/0953-8984/21/37/375104
Saida, Junji, et al. "Evaluation of the local environment for nanoscale quasicrystal formation in Zr(80)Pt(20) glassy alloy using Voronoi analysis." Journal of physics. Condensed matter : an Institute of Physics journal vol. 21,37 (2009): 375104. doi: https://doi.org/10.1088/0953-8984/21/37/375104
Saida J, Itoh K, Sato S, Imafuku M, Sanada T, Inoue A. Evaluation of the local environment for nanoscale quasicrystal formation in Zr(80)Pt(20) glassy alloy using Voronoi analysis. J Phys Condens Matter. 2009 Sep 16;21(37):375104. doi: 10.1088/0953-8984/21/37/375104. Epub 2009 Aug 11. PMID: 21832335.
Copy Download .nbib Format: NLM
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.

Oncotarget

Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R, Aoki M, Imafuku K, Okuhira H, Furudate S, Hidaka T, Aiba S.
PMID: 29643991
Oncotarget. 2018 Feb 15;9(21):15542-15551. doi: 10.18632/oncotarget.24509. eCollection 2018 Mar 20.

Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti-PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or...

Cite
Fujimura T, Sato Y, Tanita K, et al. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. Oncotarget. 2018;9(21):15542-15551doi: 10.18632/oncotarget.24509.
Fujimura, T., Sato, Y., Tanita, K., Kambayashi, Y., Otsuka, A., Fujisawa, Y., Yoshino, K., Matsushita, S., Funakoshi, T., Hata, H., Yamamoto, Y., Uchi, H., Nonomura, Y., Tanaka, R., Aoki, M., Imafuku, K., Okuhira, H., Furudate, S., Hidaka, T., & Aiba, S. (2018). Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. Oncotarget, 9(21), 15542-15551. https://doi.org/10.18632/oncotarget.24509
Fujimura, Taku, et al. "Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study." Oncotarget vol. 9,21 (2018): 15542-15551. doi: https://doi.org/10.18632/oncotarget.24509
Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R, Aoki M, Imafuku K, Okuhira H, Furudate S, Hidaka T, Aiba S. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. Oncotarget. 2018 Feb 15;9(21):15542-15551. doi: 10.18632/oncotarget.24509. eCollection 2018 Mar 20. PMID: 29643991; PMCID: PMC5884646.
Copy Download .nbib Format: NLM
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma.

Frontiers in oncology

Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R, Aoki M, Imafuku K, Okuhira H, Wada N, Irie H, Hidaka T, Hashimoto A, Aiba S.
PMID: 30510916
Front Oncol. 2018 Nov 19;8:530. doi: 10.3389/fonc.2018.00530. eCollection 2018.

Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs survival in patients with metastatic melanoma, and sequential administration with lipilimumab may improve outcomes...

Cite
Fujimura T, Sato Y, Tanita K, et al. Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma. Front Oncol. 2018;8:530doi: 10.3389/fonc.2018.00530.
Fujimura, T., Sato, Y., Tanita, K., Kambayashi, Y., Otsuka, A., Fujisawa, Y., Yoshino, K., Matsushita, S., Funakoshi, T., Hata, H., Yamamoto, Y., Uchi, H., Nonomura, Y., Tanaka, R., Aoki, M., Imafuku, K., Okuhira, H., Wada, N., Irie, H., Hidaka, T., Hashimoto, A., & Aiba, S. (2018). Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma. Frontiers in oncology, 8530. https://doi.org/10.3389/fonc.2018.00530
Fujimura, Taku, et al. "Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma." Frontiers in oncology vol. 8 (2018): 530. doi: https://doi.org/10.3389/fonc.2018.00530
Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R, Aoki M, Imafuku K, Okuhira H, Wada N, Irie H, Hidaka T, Hashimoto A, Aiba S. Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma. Front Oncol. 2018 Nov 19;8:530. doi: 10.3389/fonc.2018.00530. eCollection 2018. PMID: 30510916; PMCID: PMC6252386.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 107 entries